On June 3, 2021 Isofol reported that it will present an abstract at the annual ASCO (Free ASCO Whitepaper) meeting between June 4 – June 8 (Press release, Isofol Medical, JUN 3, 2021, View Source [SID1234583451]). Together with scientists from Sahlgrenska University Hospital and Precision for Medicine/QuartzBio (Geneva, Switzerland), we will present data about the regulation of 5-FU/folate-based treatment in colorectal cancer. MYC activation, a known transcriptional regulator of TYMS (the gene coding for TS), and one of the targets for the treatment, has been identified as a potentially relevant common upstream controller of a group of genes involved in 5-FU/folate efficacy. This relationship opens up for exploring further potential biomarker candidates as factors in 5-FU/Arfolitixorin efficacy and also combinations (including MYC-inhibitors).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Information about the presentation

Title: MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer

Authors: David A. Drubin, Anne-Katrin Hess, Natalie L. Catlett, Alessandro Di Cara, Yvonne Wettergren, Roger Tell

Abstract Number: e15512

Session title: Gastrointestinal Cancer—Colorectal and Anal